New Evidence in First-Line AML & Exploring Outcomes with Fixed-Duration Treatment in CLL

Tuesday, November 17, 2020, 6:00 PM ET

Thomas LeBlanc, MD, MA, MSH, FAAHPM Associate Professor, Division of Hematologic Malignancies and Cellular Therapy Department of Medicine, Duke University, Durham, NC

Nakhle Saba, MD Associate Professor of Medicine, Section of Hematology and Medical Oncology Tulane University, New Orleans, LA

REGISTER via link below:

https:// abbvie.meintl.com/00071-OB22-20

DURING THIS INTERACTIVE PROGRAM WE WILL:

• Recognize VENCLEXTA as a BCL-2 inhibitor for 1L AML, and 1L and R/R CLL • Review the phase 3 efficacy and safety outcomes of VENCLEXTA + azacitidine from the pivotal VIALE-A study

for patients with 1L AML, ineligible for intensive induction chemotherapy due to age or comorbidities • Explore the efficacy and safety outcomes of VENCLEXTA’s chemo-free, fixed duration CLL regimens